Bladder Cancer: Transforming the Field


Saturday, May 18

Sunday, May 19

Monday, May 20

Tuesday, May 21

Saturday, May 18

Welcome and Opening Keynote Session
6:30-7:30 p.m.

Welcome Remarks
Dan Theodorescu, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California

The epigenetics of cancer
Peter A. Jones, Van Andel Research Institute, Grand Rapids, Michigan

Welcome Reception

7:30-9:30 p.m.

Sunday, May 19

Continental Breakfast
7-8 a.m.

Session 1: Molecular Pathology – Omics, Subtypes, Biomarkers
Session Chair: Donna E. Hansel, Oregon Health & Science University, Portland, Oregon
8-10 a.m.

Molecular subtypes and liquid biopsies for predicting outcome in bladder cancer
Lars Dyrskjøt, Aarhus University Hospital, Aarhus, Denmark

Molecular subtypes of bladder cancer: Toward a more granular description of cancer heterogeneity
David J. McConkey, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, Maryland

Molecular alterations in variant morphology
Donna E. Hansel

The shifting landscape of genomics: Impact on clinical decision making
Seth P. Lerner, Baylor College of Medicine, Houston, Texas

Novel role of ketone body metabolism in acquired gemcitabine resistance*
Krizia Rohena-Rivera, Cedars-Sinai Medical Center, Los Angeles, California


10-10:30 a.m.

Session 2 and Panel Discussion: Urine Molecular Diagnosis
Session Chair: Tahlita C.M. Zuiverloon, University of Colorado Denver, Aurora, Colorado
10:30 a.m.-12:30 p.m.

A urine assay to triage patients with hematuria for cystoscopy
Joep de Jong, Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands

Potential benefits and obstacles to use of urine-based tumor markers
Yair Lotan, UT Southwestern Medical Center, Dallas, Texas

Incorporating proteomics in bladder cancer molecular diagnosis
Antonia Vlahou, Biomedical Research Foundation Academy of Athens, Athens, Greece

Profiling intra-tumoral heterogeneity of bladder cancer subtypes at the single-cell level using machine-learning assisted histopathology*
Andries Zijlstra, Vanderbilt University Medical Center, Nashville, Tennessee

Panel Discussion

Poster Session A / Lunch

12:30-3 p.m.

Plenary Session 3: Drivers of Disease – Stem Cells, Molecular Pathways, Tumor Microenvironment

Session Chair: William Y. Kim, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
3-5 p.m.

Collagen microenvironment in the modulation of local invasion and distal metastasis
Keith S. Chan, Baylor College of Medicine, Houston, Texas

Developing rational combination therapy with checkpoint inhibitors
Dan Theodorescu, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California

Chemotherapy remodels the bladder cancer immune microenvironment
William Y. Kim

Can immunological biomarkers (CD4/CD8/CD25/CD138) predict tumor recurrence and progression in NMIBC?*
Melinda Lillesand, Stavanger University Hospital, Stavanger, Norway

Tumor immune microenvironment drives prognostic relevance correlating with bladder cancer subtypes*
Markus Eckstein, University Hospital Erlangen, Erlangen, Germany

Monday, May 20

Continental Breakfast
7-8 a.m.

Session 4: Basic and Translational Immuno-Oncology
Session Chair: Charles G. Drake, Columbia University Medical Center, New York, New York
8-10 a.m.

Basic immunological mechanisms of PD-1/PD-L1 blockade
Gordon Freeman, Dana-Farber Cancer Institute, Boston, Massachusetts

NK cell activation and inactivation in the tumor microenvironment: Potential for mobilizing NK cells for cancer therapy
David H. Raulet, UC Berkeley, Berkeley, California

Genetic risk for skin autoimmunity impacts the safety and efficacy of immune checkpoint blockade in urothelial carcinoma^
Matthew Albert, insitro, South San Francisco, California

Novel immunotherapy combinations for bladder cancer
Charles G. Drake


10-10:30 a.m.

Plenary Session 5: Models for Discovery 

Session Chair: Dan Theodorescu, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California
10:30 a.m.-12:45 p.m.

Genetic mouse models and organoids: Synergy for functional genomics of bladder cancer genes
Francisco X. Real, Spanish National Cancer Center (CNIO), Madrid, Spain

Patient-derived organoid models of bladder cancer
Michael M. Shen, Columbia University College of Physicians & Surgeons, New York, New York

Genetic modeling of bladder cancer in the post-genome era
Xue-Ru Wu, NYU School of Medicine, New York, New York

PDX and genetic mouse models for deciphering signaling pathways in bladder cancer
François R. Radvanyi, Institut Curie, Paris, France

Similarities in molecular subtypes and subtype immune patterns between naturally-occurring canine and human invasive bladder cancer*
Deborah Knapp, Purdue University, West Lafayette, Indiana

Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy*
Andrew Hsieh, Fred Hutchinson Cancer Research Center, Seattle, Washington

Free Time (Lunch on Own)

12:45-3:30 p.m.

Session 6: Management of Noninvasive Disease
Session Chair: Peter C. Black, University of British Columbia, Vancouver, BC, Canada
3:30-5 p.m.

Intravesical versus systemic therapy: Win, lose, or draw – The future is now for multidisciplinary NMIBC drug development
Noah M. Hahn, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Intravesical gene therapy for NMIBC
Colin P.N. Dinney, The University of Texas MD Anderson Center, Houston, Texas

Realizing the potential of targeted therapy in non-muscle invasive bladder cancer
Peter C. Black

Poster Session B / Reception

5-7:30 p.m.

Tuesday, May 21

Continental Breakfast
7-8 a.m.

Plenary Session 7: Neoadjuvant and Bladder-Sparing Approaches to Invasive Disease
Session Chair: Jason A. Efstathiou, Massachusetts General Hospital, Boston, Massachusetts
8-10 a.m.

Recent clinical advances in trimodality therapy including combining immunotherapy with chemoradiation
Jason A. Efstathiou

Predictive biomarkers of response to neoadjuvant therapy
Kent W. Mouw, Dana-Farber Cancer Institute, Boston, Massachusetts

Molecular biomarkers of chemoradiation response in bladder preservation therapy
David T. Miyamoto, Massachusetts General Hospital, Boston, Massachusetts

Targeting hypoxia and personalizing chemoradiation
Catharine West, University of Manchester, Manchester, United Kingdom

Development of a biomarker-based nomogram to predict the pathologic response to neoadjuvant pembrolizumab in muscle-invasive urothelial bladder cancer (MIBC)*
Andrea Necchi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy


10-10:20 a.m.

Plenary Session 8: Management of Metastatic Disease
Session Chair: Dean F. Bajorin, Memorial Sloan Kettering Cancer Center, New York, New York
10:20 a.m.-12 p.m.

New agents in metastatic urothelial carcinoma
Andrea B. Apolo, National Cancer Institute, Bethesda, Maryland

Shaping the future of treatment for metastatic disease: Current standards of care and the clinical trial landscape
Dean F. Bajorin

The genomic landscape of metastatic urothelial carcinoma from circulating tumor DNA*
Gillian Vandekerkhove, Vancouver Prostate Centre, Vancouver, BC, Canada

Gene expression profiling in wild type and mutant FGFR3 metastatic urothelial cancer treated with combination therapy with vofatamab and pembrolizumab*
Woonyoung Choi, Johns Hopkins School of Medicine, Baltimore, Maryland

Closing Remarks / Discussion

12 p.m.

*Short talk from proffered abstract
^Not eligible for CME credit

Top of page